ALX Oncology Holdings Inc (ALXO) FinancialsALXOALX Oncology Holdings Inc

Evaluating the bottom line, ALX Oncology Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.65%, provide a clear picture of how effectively ALXO converts its operational activities into shareholder value.

In the context of the broader market, ALXO competes directly with industry leaders such as AVXL and TRDA. With a market capitalization of $271.02M, it holds a significant position in the sector. When comparing efficiency, ALXO's gross margin of N/A stands against AVXL's N/A and TRDA's 100.00%. Such benchmarking helps identify whether ALX Oncology Holdings Inc is trading at a premium or discount relative to its financial performance.

ALX Oncology has reported a net income loss of -$17,927,000 for Q1 2026 and a consistent negative EPS trend, with the latest EPS at -0.17. The company's current ratio is strong at 9.71, indicating good liquidity, but the overall financial performance shows significant losses.